Efficacy of “mucoregulatory” agents in Young’s syndrome

D C CURRIE, M GREENSTONE, D PAVIA, J E AGNEW, P PELLOW, S W CLARKE, W F HENDRY, P J COLE

From the Host Defence Unit, Department of Thoracic Medicine, Cardiothoracic Institute, Brompton Hospital; the Department of Thoracic Medicine, Royal Free Hospital School of Medicine; and the Department of Urology, St Bartholomew’s Hospital, London

ABSTRACT Eight patients with Young’s syndrome were treated with four “mucoregulatory” agents for eight weeks in a randomised, open crossover study. There was no improvement in tracheobronchial clearance, pulmonary function, or sperm count.

Young’s syndrome (obstructive azoospermia and sinusitis with chronic bronchitis or bronchiectasis) is a condition of unknown aetiology in which nasal and tracheobronchial clearance is abnormal. We have previously shown that nasal ciliary beat frequency and ultrastructure are normal, thereby excluding a generalised ciliary defect as the underlying cause. A secretory defect resulting in abnormal respiratory mucus and genital secretions might explain both the impaired mucociliary clearance and the observation of sperm impaction in inspissated secretions in the caput region of the epididymis. The mucoregulatory agents used in the present study have in vitro effects on mucus.

We report the effect of four reputedly mucoregulatory agents on tracheobronchial clearance, seminal fluid sperm counts, and pulmonary function in eight subjects with Young’s syndrome.

Patients and methods

Eight men, mean age 37 (range 33–40) years, were studied. Six had never smoked, one had stopped smoking 17 years ago (four pack years), and one was a current smoker (nine pack years). Mean forced expiratory volume in one second (FEV1) was 76% (range 24–107%) predicted. Four had an FEV1 below 80% predicted with an obstructive ventilatory defect and the FEV1, improved by over 10% after inhalation of salbutamol in two. The patient with an FEV1 of 24% predicted had only one lung, having had a right pneumonectomy for bronchiectasis. All had evidence of bronchiectasis, one from the pathological examination of a pneumonectomy specimen, five from bronchoography, one from computed tomography, and one from plain chest radiography. All had undergone exploratory surgery because of azoospermia and had typical findings at operation—namely, dilatation of the caput epididymis, which contained amorphous yellow fluid proximal to an apparent obstruction. All were azoospermic before and after surgery and had clinical or radiological evidence of sinusitis. Patients were asked not to change their routine drug treatment (inhaled salbutamol and beclomethasone in three, additional oral aminophylline in one, and oral prednisolone in one) or postural drainage regimen during the study. Inhaled bronchodilators and oral aminophylline were omitted for 12 hours before measurement of tracheobronchial clearance.

Tracheobronchial clearance was measured after inhalation of polystyrene particles 5 μm in diameter labelled with technetium-99m, retained radioactivity in the chest being monitored half hourly with suitably collimated scintillation counters over the first six hours. Each measurement was corrected for physical decay of the radioactive tracer. The amount of radioaerosol retained at 24 hours (alveolar deposition) was subtracted from the amount of radioaerosol retained at each timepoint to yield the amount still available for tracheobronchial clearance. The value at 6 hours and the area under the tracheobronchial retention curve (AUC) plotted over six hours were used as measures of tracheobronchial clearance. Sputum wet weight during each six hour period was measured.

Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured with a recording spirometer.

Seminal analysis was performed with a Neubauer chamber.

A randomised open crossover study design was used. After initial assessment in hospital and baseline measurement, patients received orally each of the following drugs: ambroxol (Mucosolvon, Boehringer Ingelheim) 60 mg twice daily; bromhexine (Bisolvon, Boehringer Ingelheim) 60 mg four times daily; N-acetylcysteine (Fabrol, Ciba Geigy) 200 mg thrice daily; and carbocisteine (Mucodyne, Berk Pharmaceuticals) 750 mg four times daily for no less than eight weeks each. The patients were highly motivated to comply with these treatments as they had a theoretical chance of achieving fertility. Tracheobronchial clearance and pulmonary function tests and seminal analysis were performed during the last week of each treatment. The non-parametric Wilcoxon signed rank test for paired data was used to assess the statistical significance of any change.

Results

No significant changes in tracheobronchial clearance were observed during the study (table). The mean (SEM) number of coughs during the six hour test period was 14 (5) and the
Efficacy of “mucoregulatory” agents in Young’s syndrome

Mean pulmonary function and tracheobronchial clearance indices (means with standard errors in parentheses)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>AMB</th>
<th>BHX</th>
<th>NAC</th>
<th>CC</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁(1)</td>
<td>2.72(0.36)</td>
<td>2.57(0.37)*</td>
<td>2.65(0.38)</td>
<td>2.51(0.38)†</td>
<td>2.53(0.34)†</td>
</tr>
<tr>
<td>FVC(1)</td>
<td>4.04(0.36)</td>
<td>3.91(0.36)</td>
<td>3.87(0.39)</td>
<td>3.89(0.39)</td>
<td>3.88(0.34)</td>
</tr>
<tr>
<td>TBC₅₀(%)</td>
<td>24(9)</td>
<td>28(7)</td>
<td>31(9)</td>
<td>26(6)</td>
<td>28(10)</td>
</tr>
<tr>
<td>TBC₅₀(%)</td>
<td>296(40)</td>
<td>293(44)</td>
<td>307(52)</td>
<td>310(31)</td>
<td>340(42)</td>
</tr>
</tbody>
</table>

*p = 0.05; †p < 0.05; ‡p = 0.01.

AMB—ambrroxol; BHX—bromhexine; NAC—N-acetylcysteine; CC—carbocisteine; TBC₅₀—percentage of initial radioaerosol available for tracheobronchial clearance remaining at 6 hours; AUC—area under tracheobronchial clearance curve.

Before treatment all patients were azoospermic. Six of the eight patients remained azoospermic after each treatment. Three seminal analyses from the other two patients showed more than 10⁶ spermatozoa, but their timing was not related to a particular treatment.

Discussion

The fall in FEV₁ after three of the study drugs was expected. The baseline data were obtained in hospital at the beginning of the study, when the patients might have been more motivated to perform well in the tests and take their ancillary drugs regularly than at the follow up assessments performed later in the study when they were outpatients. This rather than a drug effect may explain the fall in FEV₁.

The underlying abnormality in Young’s syndrome is unknown, although it is presumed to be a mucus defect; further research is required to define the primary defect. Treatment is therefore empirical. This small study provides no evidence of benefit from short term mucoregulatory treatment in respect of tracheobronchial clearance, pulmonary function, or sperm count.

References

Efficacy of "mucoregulatory" agents in Young's syndrome.

D C Currie, M Greenstone, D Pavia, J E Agnew, P Pellow, S W Clarke, W F Hendry and P J Cole

Thorax 1988 43: 480-481
doi: 10.1136/thx.43.6.480

Updated information and services can be found at:
http://thorax.bmj.com/content/43/6/480

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/